日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A circulating protein signature for predicting severe immune-related adverse events following CAR T-cell therapy in relapsed/refractory lymphoma

一种用于预测复发/难治性淋巴瘤患者接受 CAR-T 细胞治疗后严重免疫相关不良事件的循环蛋白特征

Irajizad, Ehsan; Fahrmann, Johannes F; Katayama, Hiroyuki; Strati, Paolo; Nair, Ranjit; Chihara, Dai; Fayad, Luis E; Ahmed, Sairah; Iyer, Swaminathan P; Wang, Michael; Locke, Frederick L; Davila, Marco; Flowers, Christopher R; Shpall, Elizabeth; Neelapu, Sattva S; Hanash, Samir; Westin, Jason; Jain, Michael D; John, Teny M; Saini, Neeraj Y

A patient derived xenograft repository capturing clinical and molecular heterogeneity of large B-cell lymphoma

一个源自患者的异种移植模型库,用于捕捉大B细胞淋巴瘤的临床和分子异质性

Yang, Haopeng; Arita, Kotaro; Bowman, Kevin; Chihara, Dai; Henderson, Jared; Rost, Griffin; Rojas, Estela; Parsons, Sydney; Lakra, Priya; Abedin, Aneela; Neelapu, Sattva S; Strati, Paolo; Nastoupil, Loretta J; Fayad, Luis; Iyer, Swaminathan P; Rodriguez, Alma; Hagemeister, Frederick B; Malpica, Luis; Lee, Hun Ju; Hilton, Laura; Scott, David W; Davis, Richard Eric; Flowers, Christopher R; Westin, Jason R; Inghirami, Giorgio; Vega, Francisco; Green, Michael R

Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies

异基因嵌合抗原受体T细胞产品Cemacabtagene Ansegedleucel/ALLO-501治疗复发/难治性大B细胞淋巴瘤:ALPHA2/ALPHA临床研究的I期经验

Locke, Frederick L; Munoz, Javier L; Tees, Michael T; Lekakis, Lazaros J; de Vos, Sven; Nath, Rajneesh; Stevens, Don A; Malik, Shahbaz A; Shouse, Geoffrey P; Hamadani, Mehdi; Oluwole, Olalekan O; Perales, Miguel-Angel; Miklos, David B; Fisher, Paul W; Feng, Amy; Navale, Lynn; Le Gall, John B; Neelapu, Sattva S

Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

ZUMA-5 五年随访分析:Axicabtagene Ciloleucel 治疗复发/难治性惰性非霍奇金淋巴瘤

Neelapu, Sattva S; Chavez, Julio C; Sehgal, Alison R; Epperla, Narendranath; Ulrickson, Matthew L; Bachy, Emmanuel; Munshi, Pashna N; Casulo, Carla; Maloney, David G; de Vos, Sven; Reshef, Ran; Leslie, Lori A; Oluwole, Olalekan O; Yakoub-Agha, Ibrahim; Khanal, Rashmi; Rosenblatt, Joseph D; Wulff, Jacob; Shen, Rhine R; Zhang, Wangshu; Poddar, Soumya; Miao, Harry; Nikolajeva, Olga; Jacobson, Caron A

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

抗生素引起的肠道微生物群代谢输出下降与CAR-T细胞疗法的临床反应相关

Prasad, Rishika; Rehman, Abdur; Rehman, Lubna; Darbaniyan, Faezeh; Blumenberg, Viktoria; Schubert, Maria-Luisa; Mor, Uria; Zamir, Eli; Schmidt, Sabine; Hayase, Tomo; Chang, Chia-Chi; McDaniel, Lauren; Flores, Ivonne; Strati, Paolo; Nair, Ranjit; Chihara, Dai; Fayad, Luis E; Ahmed, Sairah; Iyer, Swaminathan P; Wang, Michael; Jain, Preetesh; Nastoupil, Loretta J; Westin, Jason; Arora, Reetakshi; Turner, Joel; Khawaja, Fareed; Wu, Ranran; Dennison, Jennifer B; Menges, Meghan; Hidalgo-Vargas, Melanie; Reid, Kayla; Davila, Marco L; Dreger, Peter; Korell, Felix; Schmitt, Anita; Tanner, Mark R; Champlin, Richard E; Flowers, Christopher R; Shpall, Elizabeth J; Hanash, Samir; Neelapu, Sattva S; Schmitt, Michael; Subklewe, Marion; Francois-Fahrmann, Johannes; Stein-Thoeringer, C K; Elinav, Eran; Jain, Michael D; Hayase, Eiko; Jenq, Robert R; Saini, Neeraj Y

Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial

一线治疗高肿瘤负荷晚期滤泡性淋巴瘤:阿卡替尼、来那度胺和利妥昔单抗联合方案:II期试验

Strati, Paolo; Feng, Lei; Westin, Jason R; Nair, Ranjit; Fayad, Luis E; Rodriguez, Maria A; Chihara, Dai; Malpica, Luis; Henderson, Jared; Gallardo, Mariana; Rivera, Marissa; Wang, Iris; Bolshakova, Anastasiia; Radko, Anastasia; Kurtz, David; Alig, Stefan K; Flowers, Christopher R; Alizadeh, Ash A; Neelapu, Sattva S

Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy

CAR-T细胞疗法治疗大B细胞淋巴瘤患者的毒性和疗效的种系决定因素

Strati, Paolo; Brandt, Amanda; Lionel, Anath C; Henderson, Jared; Westin, Jason R; Adkins, Sherry; Shpall, Elizabeth J; Kebriaei, Partow; Ramdial, Jeremy; Saini, Neeraj; Ahmed, Sairah; Flowers, Christopher; Neelapu, Sattva S; Hildebrandt, Michelle A T

A Phase I Trial of Evorpacept, Lenalidomide and Rituximab for Patients with B-cell Non-Hodgkin Lymphoma.

Evorpacept、来那度胺和利妥昔单抗治疗 B 细胞非霍奇金淋巴瘤患者的 I 期试验

Strati Paolo, Feng Lei, Tyshevich Andrey, Shavronskaya Darya, Alesse Julia, English Noel, Sheehan Elizabeth, Syzrantsev Nikita, Nesmelov Alexander, Zhuang Tony Z, Chihara Dai, Westin Jason R, Ahmed Sairah, Fayad Luis E, Henderson Jared, Dent Kylie, McChesney Elizabeth, Neelapu Sattva S, Flowers Christopher R

Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas

伊布替尼联合纳武利尤单抗治疗复发性中枢神经系统淋巴瘤患者的二期临床试验

Chihara, Dai; Steiner, Raphael E; Nair, Ranjit; Feng, Lei; Ahmed, Sairah; Strati, Paolo; Malpica, Luis; Griffith, Donna P; Mathew, Shivon A; Montinez, Wirt; Masand, Gita; Samaniego, Felipe; Rodriguez, Maria A; Hagemeister, Fredrick B; Fayad, Luis E; Iyer, Swaminathan P; Nastoupil, Loretta J; Neelapu, Sattva S; Flowers, Christopher R; Westin, Jason R

Nivolumab plus relatlimab for patients with relapsed or progressed B-cell malignancies in RELATIVITY-022

在 RELATIVITY-022 研究中,Nivolumab 联合 relatlimab 用于治疗复发或进展性 B 细胞恶性肿瘤患者

Gopal, Ajay K; Armand, Philippe; Neelapu, Sattva S; Bartlett, Nancy L; Spurgeon, Stephen E; Kuruvilla, John; Savage, Kerry J; Leonard, John P; Gelb, Arnold B; Ahmed, Nasir; Dong, Shiqi; Bathena, Sai Praneeth; Suryawanshi, Rasika; Wu, Jenny Qun; Wang, Sheen; Gladstone, Douglas E